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ABSTRACT 
Objective: The objective of the current study was to explore top down methods of size reduction like high speed homogenisation and media milling 
in synergism with spray drying in amorphization and solubility enhancement of BCS Class II antilipidemic drug Simvastatin USP.  
Methods: Spray-dried micronized simvastatin USP was formulated by homogenisation and media milling of drug suspension in optimized stabilizer 
solution. Stabilizer combination, duration of homogenisation and ball milling and drug: stabilizer ratio was optimized. The obtained dispersion was 
transformed into solid powder using spray drying. The obtained Spray-dried micronized Simvastatin USP was evaluated for visual morphology, 
Infrared spectroscopy, Differential scanning calorimetry, in vitro drug release studies, X-Ray diffractometry, Scanning electron microscopy, contact 
angle measurement, solubility studies, dispersibility studies and intrinsic dissolution rate testing. 
Results: Spray-dried micronized simvastatin USP was found to show amorphization of crystalline Simvastatin USP as confirmed by the absence of 
drug peak in Differential scanning calorimetry and lowered signal intensity in X-Ray diffraction studies. Spray-dried micronized Simvastatin USP 
was found to show enhanced drug hydrophilicity and solubility as confirmed by lowering in contact angle and increase in solubility and ease of 
dispersibility observations. In vitro dissolution testing and intrinsic dissolution rate testing were found to show an increase in drug release from 
11% to 79% and 4 mg min-1 cm-2 to 17 mg min-1 cm-2 for drug and Spray-dried micronized Simvastatin USP respectively.  
Conclusion: Media milling in synergism with spray-drying was found to be a prospective solubility enhancement technique for poorly-soluble 
Simvastatin USP.  
Keywords: Simvastatin, Solubility enhancement, Media milling, Spray drying, Stabilizer, Amorphization, Contact angle, Homogenization 
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INTRODUCTION 
Different active pharmaceutical ingredients discovered via high 
throughput screening or combinatorial chemistry have been attempted 
in designing of dosage form for oral administration as the oral route is 
very convenient in terms of patient administration of the dosage form [1, 
2]. The poor solubility characteristics of pharmacologically active 
lipophilic compounds greatly affect their bioavailability and pose a 
challenge to formulation scientists in designing suitable bioavailable 
dosage forms [3-5]. This issue is often seen for BCS Class II drugs 
exhibiting high permeability but poor solubility [6].  
The differences observed in the physicochemical attribute of 
solubility for solid drugs are due to differences in solid state 
properties mainly the long range periodicity of the molecules [7]. 
Pharmaceutical solids existing in amorphous form are high energy 
systems which exhibit higher solubility and faster dissolution 
velocities and hence are preferred over crystalline forms [8]. 
Different arrangements of lattice structure give rise to distinct 
crystalline forms of drugs exhibiting variable aqueous solubility. 
Hence modulations in drug crystalline characteristics can pave a 
way for modulations in solubility of the drug [9]. 
Use of solvents and surfactants in solubility enhancement can lead to 
precipitation and toxicity issues resulting in the need to conduct more 
stringent toxicity studies [10-12]. Further several innovative 
approaches like cyclodextrin complexation, solid dispersions, 
dendrimeric conjugation, liquisolid compaction, self microemulsifying 
drug delivery systems etc attempted for solubility enhancement have 
exhibited lesser commercial viability owing to the high cost, complex 
formulation steps and analytical procedures [13, 14]. 
Particle size reduction of poorly soluble drugs has been widely 
explored to enhance drug solubility and thus dissolution rate [15, 16] 
Size reduction to lower size ranges and nanonization to size less 
than 500 nm is accompanied by increase in surface area which 
consequently aids to enhance the drug saturation solubility and 
hence the dissolution rate as per the Nernst Brunner/Noyes 
Whitney equation and the Ostwald-Freundlich equation [17, 18]. For 
solubility enhancement, techniques like High shear homogenisation 
(HSH), Media milling, Jet milling (JM) etc. can be explored for 
micronization and nanonization of pharmaceutical drugs [19-21]. 
Simvastatin USP; a BCS Class II drug is used widely as a cholesterol 
and lipid lowering agent in hypercholesteremia and dyslipidemia 
[22]. Structure of Simvastatin is shown in fig. 1. Simvastatin USP 
exhibits its antilipidemic activity by generating a β-hydroxy acid 
form as a metabolite that inhibits the rate limiting step of conversion 
of HMG Co-A to mevalonate in cholesterol synthesis. Simvastatin 
USP shows poor aqueous solubility and hence low bioavailability of 
less than 5% which makes designing of bioavailable dosage forms a 
challenging task [23]. 
 
 
Fig. 1: Structure of simvastatin USP drug 
 
The primary focus of the current research work was to evaluate the 
effect of top down methods of size reduction like high speed 
International Journal of Pharmacy and Pharmaceutical Sciences 
Print ISSN: 2656-0097 | Online ISSN: 0975-1491                          Vol 12, Issue 11, 2020 
Amin et al. 
Int J Pharm Pharm Sci, Vol 12, Issue 11, 114-121 
115 
homogenization and media milling in synergism with spray-drying 
on the crystalline characteristics, solubility and dissolution rate of 
Simvastatin USP. 
MATERIALS AND METHODS 
Simvastatin USP was a gift from Biocon Ltd, Bangalore, India. 
Lutrol F68, Lutrol F127 and Vitamin E TPGS were gifted by BASF 
India, Turbhe, Mumbai. HPMC E15 was gifted by Coloron India, 
Mumbai. Sodium lauryl sulphate was purchased from SD Fine 
Chemicals Ltd, Mumbai, India. Mannitol was gifted by DFE 
Pharma, Mumbai, India. A laboratory-scale media mill of volume 
500 ml fabricated by S. F. Engineering works, India was used for 
size reduction of drug. Remi Motors RQ-127 homogenizer was 
used for homogenization. JISL LSD 48 Spray drier was used for 
spray drying. 
Formulation of Simvastatin micronized suspension 
The stabilizer system for micronized Simvastatin USP suspension 
was optimized by determining the contact angle of surfactant 
solutions like Lutrol F68, Lutrol F127, HPMC E15, PVPK30, Sodium 
lauryl sulphate and Kolliphor ® TPGS (d-alpha tocopheryl 
polyethylene glycol 1000 succinate) with drug in a concentration of 
0.5% and 0.25% as single surfactant system and in combination with 
Sodium lauryl sulphate respectively using Kruss contact angle meter 
and sessile drop method [25]. Coarse suspension of Simvastatin USP 
in distilled water was prepared using the obtained optimised 
stabiliser system in the ratio of 5:1 and 2:1. The formula for coarse 
suspension subjected to homogenization and ball milling is as shown 
in table 1. Balls of two different dimensions; 22 balls of 19 mm and 
27 balls of 14 mm were considered for the ball milling process 
conducted occupying more than 50% of ball mill volume. 
  
Table 1: Formula for coarse suspension to be homogenized and ball milled 
 Quantity in % w/100 ml 
for ratio 5:1  
Quantity for 300 ml (in 
gms) for ratio 5:1 
Quantity in % w/100 
ml for ratio 2:1 
Quantity for 300 ml (in 
gms) for ratio 2:1 
Simvastatin USP 2.5 7.5 2.5 7.5 
Lutrol F68 0.25 0.75 0.625 1.875 
Sodium Lauryl Sulphate 0.25 0.75 0.625 1.875 
Distilled water q. s q. s to 100 ml q. s to 300 ml q. s to 100 ml q. s to 300 ml 
 
The coarse suspension of Simvastatin USP containing optimised 
stabiliser system in the ratio of 5:1 was subjected to 4 h of High 
speed homogenisation at 800 rpm and 48 h of ball milling at 21 rpm. 
Particle size of micronized suspension was determined using 
Malvern Hydro 2000 particle size analyser after every hour. 
Duration of high speed homogenisation and media milling for 
effective size reduction was optimized using d (0.9) and D [4, 3] 
values of particle size measurement. Based on size observations 
with 5:1 ratio of drug: stabilizer, the coarse suspension containing 
Simvastatin USP and the optimised stabiliser system in the ratio of 
2:1 was subjected to 1hour of High speed homogenisation at 800 
rpm and 24 h of ball milling at 21 rpm. The obtained micronized 
Simvastatin USP suspension was transformed into solid powder 
using Spray drying technique and Mannitol as the carrier in drug: 
carrier ratio of 1:2. Spray drying parameters was optimized to get 
best yield of amorphized micronized spray-dried drug. 
Evaluation studies 
Morphology studies 
Morphological details of obtained spray-dried micronized 
Simvastatin USP were studied and compared to Simvastatin USP 
drug using Canon power shot 480 digital camera.  
FTIR studies 
Characteristic chemical bands for Simvastatin USP drug and spray-
dried micronized simvastatin USP were studied using Shimadzu 
miracle IR affinity-1 FTIR spectrophotometer. The spray-dried 
micronized Simvastatin USP sample was scanned between 400 cm-1 
to 4000 cm-1 using air as the standard using attenuated total 
reflection probe technique.  
Differential scanning calorimetry studies 
The melting characteristics of the spray-dried micronized simvastatin 
USP were studied using Pyris 6 Perkin Elmer Differential scanning 
calorimeter (DSC). 3-4 mg of the micronized Simvastatin USP was 
placed in an aluminium pan. The pan was covered with lid and 
crimped using DSC crimper. The crimped pans were heated against 
blank crimped pans from 30 °C to 300 °C at 10 °C/min under nitrogen 
flow of 17 ml/min and obtained endothermic peaks were studied. 
X-ray diffraction studies 
The crystalline characteristics of spray-dried micronized simvastatin 
USP were studied using Bruker D8 Advance XRD analyzer. 1.5 gm of 
spray-dried micronized Simvastatin USP sample was placed on a 
sample holder and the sample holder was placed on a rotating 
sample stage. The sample in the holder was placed in the horizontal 
position and the X-ray tube and detector were moved over the 
sample simultaneously to cover the 2-theta angular range from 2 to 
50. The crystalline characteristics were studied from the obtained 
signal plot of intensity versus 2-theta values. 
Contact angle measurement studies 
The wetting tendency of the spray-dried micronized simvastatin USP 
was determined using Kruss contact angle goniometer by the sessile 
drop method. Spray-dried micronized simvastatin USP were 
converted into flat compacts using Hydraulic press and the angle 
made by a water drop placed horizontally on the flat surface was 
measured using inbuilt cross wires and optical eyepiece assembly. 
The wetting tendency of spray-dried micronized Simvastatin USP 
was compared with Simvastatin USP [24]. 
In vitro drug release testing 
The in vitro drug release for Simvastatin USP and spray-dried 
micronized simvastatin USP was studied using USP Dissolution 
Apparatus II-Paddle type. 40 mg Simvastatin USP and an amount of 
spray-dried micronized simvastatin USP equivalent to 40 mg (140 
mg) were weighed and placed in hard gelatin capsules size 00. The 
capsules containing spray-dried micronized simvastatin USP were 
clamped using sinkers and placed in 900 ml of 0.01 M Phosphate 
buffer pH 7 containing 0.5% SLS. The dissolution procedure was 
conducted at 50 rpm at 37±0.5 °C. Aliquots of 5 ml were taken at 15, 
30, 45, 60, 90 and 120 min and filtered using a 0.45 micron filter. 5 
ml of the aliquot sample was replaced with buffer medium to 
maintain sink conditions. Absorbance of the aliquot samples was 
measured at 238 nm using buffer medium as reference. The drug 
release was calculated from the standard plot of Simvastatin USP in 
0.01 M Phosphate buffer pH 7 containing 0.5% SLS.  
Solubility studies 
Solubility studies of Simvastatin USP and spray-dried micronized 
simvastatin USP were conducted using a constant temperature 
water shaker bath. 10 mg of Simvastatin USP and spray-dried 
micronized simvastatin USP equivalent to 10 mg of Simvastatin USP 
were added to 10 ml water. The dispersion was shaken for 48 h at 
37 °C. The resulting solution was filtered using 0.45μ filter and the 
absorbance of the filtrate was determined using ultraviolet 
spectroscopy at 238 nm. The solubility was calculated from the 
determined absorbance using standard plot. 
Scanning electron microscopy (SEM) studies 
The fine morphological details of the spray-dried micronized 
simvastatin USP were studied using a Philips XL 30 Scanning 
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electron microscope. The samples were loaded on aluminium stub 
with conductive double sided adhesive tape, coated with gold in an 
argon atmosphere (50 Pa) at 50mA for 50 secs. The samples were 
scanned at a voltage of 20kv. 
Dispersibility studies 
The aqueous dispersibility of spray-dried micronized simvastatin 
USP was determined which was then compared to Simvastatin USP. 
1g of Simvastatin USP and spray-dried micronized simvastatin USP 
was added to 100 ml water and the speed and ease of dispersion was 
observed and compared.  
Intrinsic dissolution rate determination 
Intrinsic dissolution of spray-dried micronized simvastatin USP was 
determined by rotating disc method (Wood’s apparatus). 
Simvastatin USP sample and spray-dried micronized simvastatin 
USP were pressed in between the die and punch of the intrinsic 
dissolution rate paddle assembly to arrive at a constant flat surface 
area. The paddles were exposed to 0.01 M Phosphate buffer pH 7 
containing 0.5% SLS and the dissolution rate per square centimetre 
was calculated [25]. 
RESULTS  
Formulation of Spray-dried micronized Simvastatin USP 
suspension:  
A combination of 0.25% Lutrol F68 and 0.25% sodium lauryl 
sulphate was found to show maximum wetting as indicated by 
highest lowering of the contact angle and hence was considered for 
further micronization studies. The contact angles of single and 
combination stabilizer solutions are as shown in fig. 2. 
 
 
Fig. 2: Contact angle measurement results for stabilizer optimization 
 
For the drug: stabilizer ratio of 5:1, 1 hour of high speed 
homogenization was found to show the maximum lowering in drug 
particle size. Homogenization of the suspension for 2, 3 and 4 h was 
found to show an insignificant effect on the drug particle size. Further 
ball milling for 24 h was found to show lowering in particle size 
whereas 48 h of milling was found to enhance the size. The particle 
size of suspension subjected to homogenisation and ball milling for 
different durations is as shown in table 2. The enhancement in size 
may be contributed to the initiation of aggregation phenomena owing 
to soft nature of Simvastatin USP and the relatively lesser amount of 
stabilizer. Hence 1 hour of high speed homogenisation and 24 hour of 
ball milling was considered as the optimized duration. Based on the 
particle size lowering, a drug: stabilizer ratio of 5:1 was found to be 
effective and considered for further studies. 
  
Table 2: Particle size measurement of suspension after homogenisation and ball milling for different durations 
Duration of homogenization(HSH)/ 
ball milling(BM) 
d(0.1) in microns d(0.5) in microns d(0.9) in microns D[4,3] 
Drug: stabilizer 5:1     
Plain Simvastatin USP 11.7±0.12 27.3±0.07 73.1±0.15 41.1±0.33 
1 hr HSH 6.4±0.25 15.7±0.13 34.7±0.26 19.5±0.16 
2 hr HSH 4.7±0.42 14.8±0.37 36.2±0.17 18.6±0.23 
3 hr HSH 4.2±0.36 14.6±0.29 36.5±0.42 18.6±0.34 
4 hr HSH 4.1±0.47 14.5±0.06 36.5±0.38 18.6±0.29 
24 BM 1.8±0.16 10.9±0.23 31.6±0.09 16.4±0.43 
48 h BM 1.9±0.32 11.9±0.36 115.4±0.18 33.9±0.05 
Drug: stabilizer 2:1     
1 hr HSH 5.4±0.34 15.1±0.18 37.6±0.21 19.2±0.35 
24 hr BM 2.8±0.16 11.9±0.13 34.5±0.32 16.2±0.26 
Data is given in mean±standard deviation (SD) for n=3 
 
Spray drying of the micronized drug suspension loaded on a carrier 
at the optimized spray-drying parameters was found to yield free 
flowing white coloured powder. The optimized spray drying 
parameters are as shown in table 3. 
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Table 3: Optimized spray drying parameters 
Parameter Observation 
Inlet Temperature ( °C) 131.9±0.2 
Outlet Temperature ( °C) 45±0.57 
Aspirator 52±0.90 
Feed rate (rpm) 2±0.12 
Atomizing Pressure (bars)  2.9±0.23 




Simvastatin USP drug and spray-dried micronized simvastatin 
USP was found to show distinct difference in appearance. 
Simvastatin USP was observed as shiny white fluffy powder 
whereas Spray-dried micronized Simvastatin USP was seen as a 
coarse white powder. Morphological details of Simvastatin USP 
drug and spray-dried micronized simvastatin USP are as shown 
in fig. 3. 
 
 
Fig. 3: Visual morphology a. simvastatin USP b. spray dried micronized simvastatin USP 
 
FTIR studies 
FTIR spectra of Simvastatin USP, mannitol and spray-dried 
micronized simvastatin USP are as shown in fig. 4. FTIR spectra 
of spray-dried micronized simvastatin USP was found to show 
bands characteristic for Simvastatin USP and carrier Mannitol 




Fig. 4: FTIR Spectra a. simvastatin USP b. mannitol c. spray-dried micronized simvastatin USP 
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Differential scanning calorimetry studies 
DSC endotherms for Simvastatin USP, mannitol and spray-dried 
micronized simvastatin USP are as shown in fig. 5. Simvastatin USP 
was found to show an endothermic peak at 143.47 °C whereas 
Mannitol was found to show an endothermic peak at 173.24 °C. DSC 
endotherm of spray-dried micronized simvastatin USP was found to 
show a single endothermic peak at 168.4 °C closer to that of carrier 
Mannitol. No peak for Simvastatin USP was observed thus indicating 
amorphization of crystalline drug. 
  
 
Fig.5: DSC endotherm a. simvastatin USP b. mannitol c. spray-dried micronized simvastatin USP 
 
 
Fig. 6: X-ray diffractogram a. simvastatin USP b. mannitol c. spray-dried micronized simvastatin USP 
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X-ray diffraction studies 
X-ray diffractograms of Simvastatin USP, mannitol and spray-dried 
micronized simvastatin USP are as shown in fig. 6. X-Ray 
diffractogram of spray-dried micronized simvastatin USP was 
found to show signals at 2 theta values characteristic of 
Simvastatin USP and Mannitol. A distinct decline in intensity of 
signals at 2 theta values characteristic of Simvastatin USP was 
observed in X-Ray diffractogram of spray-dried micronized 
simvastatin USP thus confirming the amorphization of Simvastatin 
USP. 
Contact angle measurement studies 
Spray-dried micronized Simvastatin USP were found to show 
drastic lowering of the contact angle from 56 °±0.23 for 
Simvastatin USP to 2°±0.10 thus indicating enhanced 
hydrophilicity and wetting tendency of spray-dried micronized 
Simvastatin USP.  
In vitro drug release testing 
Spray-dried micronized Simvastatin USP was found to show an 
increase in drug release of 79% as compared to plain drug release 
as observed to be 11%. The in vitro drug release profile for 
Simvastatin USP and spray-dried micronized simvastatin USP are 
as shown in fig. 7. 
Solubility studies 
Spray-dried micronized simvastatin USP was found to show 
increased solubility in water compared to Simvastatin USP owing to 
enhanced hydrophilicity and increased surface area of the drug. The 
measured solubility values for Simvastatin USP and spray-dried 
micronized simvastatin USP are as shown in table 4. 
Scanning electron microscopy studies 
The Spray-dried micronized simvastatin USP was found to show 
porous spherical morphology whereas Simvastatin USP and 
Mannitol were found to show needle shaped morphology. SEM 
images for Simvastatin USP, Mannitol and Spray dried micronized 
simvastatin USP are as shown in fig. 8. 
Dispersibility studies 
Spray-dried micronized simvastatin USP was found to disperse 
completely in water in less than 30 seconds forming homogenous 
white coloured solution compared to that of plain drug which 
formed non-wettable heap on the surface of water [fig. 9] 
 
 
Fig. 7: In vitro drug release of simvastatin USP and spray-dried micronized simvastatin USP (n=3, mean±standard deviation) 
 
Table 4: Solubility of simvastatin USP and spray-dried micronized simvastatin USP 
 Solubility in microgram/ml 
Simvastatin USP 3±0.5 
Spray-dried micronized Simvastatin  500±0.34 
Data is given in mean±standard deviation (SD) for n=3 
 
 
Fig. 8: SEM image a. simvastatin USP b. mannitol c. spray dried micronized simvastatin USP 
 
 
Fig. 9: Dispersibility studies of simvastatin USP and spray-dried micronized simvastatin USP 
Fig. 10: Intrinsic dissolution rate of simvastatin USP and s
 
Intrinsic dissolution rate determination 
Spray-dried micronized simvastatin USP was
increased intrinsic dissolution rate of 17 mg min
to Simvastatin USP which showed a rate of 4 mg min
DISCUSSION 
The effect of particle size reduction technique 
selection of a suitable stabilizer system depends on the p
attributes of the drug mainly the hardness of the drug. 
of non-ionic and ionic surfactant system of Lutrol F68 and s
lauryl sulphate which was found to exhibit 
contact angle for Simvastatin USP; aid in stabilization of micronized 
active Simvastatin USP in the dispersion by steric and electrostatic 
stabilization [26]. The surfactant combination also aids to influence 
the solubility by enhanced wetting. The presence of infrared bands 
characteristic for both Simvastatin USP and Mannitol
micronized simvastatin USP indicates no changes in the chemical 
properties of the drug. The effect of homogenization and ball milling 
on the drug crystallinity can be studied by DSC studies. DSC 
endotherm of Spray-dried micronized simvastatin 
show absence of drug melting peak whereas a single peak was 
observed at 168.4 °C; a temperature point closer to melting 
temperature of carrier Mannitol. Thus DSC studies aids
the amorphization effect of high speed homogenisation and ball 
milling on the crystalline Simvastatin USP. The amorphization was 
further confirmed by the XRD studies of Spray
simvastatin USP which exhibited a distinct decline in intensity of 
signals at two theta values characteristic for Simvastatin USP.
profound increase in solubility from 3±0.5 to 500
the increase in drug release from 11% to 79%
micronization, enhanced wetting and spray-
Simvastatin USP. The optimized stabilizer system aids to enhance 
the hydrophilicity of drug. The micronization process further aids to 
enhance the surface area available for dissolution in the media. 
Spray-drying of the micronized drug produces s
Simvastatin USP drug with high porosity thus aiding the 
solubilisation effect. Increase in solubilization can be further 
augmented by the presence of water soluble Mannitol as carrier of 
the micronized Simvastatin USP [27]. 
The intrinsic dissolution rate determination mainly aids to 
determine the specific surface area of the drug solid in contact with 
medium and available for dissolution. The increase in the Intrinsic 
dissolution rate of 17 mg min-1 cm-2 for Spray
simvastatin USP as compared to 4 mg min-1 cm-
aid to confirm the increase in surface area due to drug 
micronization. The increased surface area increases the saturation 
solubility of the drug which is further supported by decreased 
crystal lattice energy and enhanced wetting by surfactant 
association and the porosity imparted by spray 
CONCLUSION 
The solubility of drugs can be improved by 
physicochemical attributes. A synergism of pa
Amin et al. 
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pray-dried micronized simvastatin USP (n=3
 found to exhibit an 
-1 cm-2 as compared 
-1 cm-2 [fig. 10] 




highest lowering in 
 in Spray-dried 
USP was found to 
 to confirm 
-dried micronized 
 The 
±0.34 µg/ml and 
 can be attributed to 
drying treatment of 
pherical micronized 
-dried micronized 
2 for Simvastatin USP 
drying process [28]. 
manoeuvring the 
rticle size reduction 
and spray drying has been widely studied to enhance solubility. 
Based on the studies conducted in
observed that homogenization and ball 
Simvastatin USP in presence of suitable stabilizers followed by 
spray-drying in presence of carrier Mannitol effectively aided to 
reduce the size and enhance the hydrophilicity and wetting 
properties of the drug. Furthermore the treatment was found
amorphize the drug thus enhancing its solubility propertie
media milling and spray drying can be attempted as prospective 
techniques for solubility enhancement for poorly
versatile therapeutic indications
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